SK282466B6 - Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK282466B6
SK282466B6 SK1653-97A SK165397A SK282466B6 SK 282466 B6 SK282466 B6 SK 282466B6 SK 165397 A SK165397 A SK 165397A SK 282466 B6 SK282466 B6 SK 282466B6
Authority
SK
Slovakia
Prior art keywords
methyl
residues
xab
tert
xaa
Prior art date
Application number
SK1653-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK165397A3 (en
Inventor
Andreas Haupt
Franz Emling
Cynthia A. Romerdahl
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of SK165397A3 publication Critical patent/SK165397A3/sk
Publication of SK282466B6 publication Critical patent/SK282466B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK1653-97A 1995-06-07 1996-06-03 Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie SK282466B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002392 WO1996040751A1 (fr) 1995-06-07 1996-06-03 Nouveaux derives de dolastatine, leur preparation et leur utilisation

Publications (2)

Publication Number Publication Date
SK165397A3 SK165397A3 (en) 1998-10-07
SK282466B6 true SK282466B6 (sk) 2002-02-05

Family

ID=23875567

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1653-97A SK282466B6 (sk) 1995-06-07 1996-06-03 Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (33)

Country Link
US (1) US5831002A (fr)
EP (2) EP0832104B1 (fr)
JP (2) JP4221062B2 (fr)
KR (2) KR100437985B1 (fr)
CN (2) CN1182153C (fr)
AR (2) AR003427A1 (fr)
AT (2) ATE224910T1 (fr)
AU (2) AU725170B2 (fr)
BG (2) BG102125A (fr)
BR (2) BR9609423A (fr)
CA (2) CA2219818C (fr)
CO (2) CO4700526A1 (fr)
CZ (2) CZ293682B6 (fr)
DE (2) DE69623992T2 (fr)
DK (2) DK0832104T3 (fr)
ES (2) ES2188759T3 (fr)
HR (2) HRP960257A2 (fr)
HU (2) HU228073B1 (fr)
IL (2) IL122216A (fr)
MX (2) MX9709147A (fr)
MY (2) MY119042A (fr)
NO (2) NO318384B1 (fr)
NZ (2) NZ310443A (fr)
PL (2) PL185763B1 (fr)
PT (2) PT871656E (fr)
RO (2) RO119783B1 (fr)
SI (2) SI0871656T1 (fr)
SK (1) SK282466B6 (fr)
TR (2) TR199701544T1 (fr)
TW (2) TW508357B (fr)
UA (2) UA46776C2 (fr)
WO (2) WO1996040751A1 (fr)
ZA (2) ZA964711B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000051998A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN1307875C (zh) 2001-04-27 2007-04-04 宝洁公司 用于控制生物膜的化合物、组合物和方法
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
EP1781310B1 (fr) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles de nanostructures a base de peptides et leur procede de formation
CA2607940C (fr) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Composes liants de domaine bir
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
WO2007043048A2 (fr) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Hydrogels auto-assembles et leurs procedes d'elaboration et d'utilisation
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
EP2049524A2 (fr) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Inhibiteurs des iap
CN101674835B (zh) * 2007-04-12 2013-12-11 台湾神隆股份有限公司 制备加兰他敏的方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (fr) 2010-12-30 2014-07-30 Enanta Pharm Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012166560A1 (fr) * 2011-05-27 2012-12-06 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
CA3230737A1 (fr) 2021-09-03 2023-03-09 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prevention du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
HUT71398A (en) * 1992-05-20 1995-11-28 Basf Ag Derivatives of dolastatin
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
EP0871656A1 (fr) 1998-10-21
AU725170B2 (en) 2000-10-05
EP0832104B1 (fr) 2002-09-04
CA2219818C (fr) 2008-05-20
MY124487A (en) 2006-06-30
BG102152A (en) 1998-09-30
HUP9801910A3 (en) 1999-06-28
EP0832104A1 (fr) 1998-04-01
AR003427A1 (es) 1998-08-05
TW424096B (en) 2001-03-01
MX9709147A (es) 1998-03-31
PL323723A1 (en) 1998-04-14
MY119042A (en) 2005-03-31
HU228073B1 (hu) 2012-09-28
BR9609423A (pt) 1999-06-29
RO119783B1 (ro) 2005-03-30
MX9709146A (es) 1998-03-31
DK0871656T3 (da) 2003-01-27
JPH11504652A (ja) 1999-04-27
CA2219819C (fr) 2008-05-20
KR100437985B1 (ko) 2004-09-18
CN1182154C (zh) 2004-12-29
SI0832104T1 (en) 2003-08-31
BG102125A (en) 1998-09-30
AR003136A1 (es) 1998-07-08
CZ293683B6 (cs) 2004-07-14
IL122215A0 (en) 1998-04-05
RO118953B1 (ro) 2004-01-30
CA2219818A1 (fr) 1996-12-19
CO4700527A1 (es) 1998-12-29
IL122215A (en) 2001-08-26
NO975710L (no) 1998-02-02
ZA964711B (en) 1997-12-08
DE69623992T2 (de) 2003-05-22
CA2219819A1 (fr) 1996-12-19
HUP9801910A2 (hu) 1999-01-28
DE69623472T2 (de) 2003-08-21
DE69623992D1 (de) 2002-10-31
JP4221062B2 (ja) 2009-02-12
BR9609424A (pt) 2000-03-28
SI0871656T1 (en) 2003-08-31
ES2186783T3 (es) 2003-05-16
ATE223431T1 (de) 2002-09-15
UA46775C2 (uk) 2002-06-17
HUP9801817A3 (en) 1999-06-28
JP3957751B2 (ja) 2007-08-15
WO1996040752A1 (fr) 1996-12-19
NZ310444A (en) 1999-11-29
CZ376597A3 (cs) 1998-06-17
AU6124196A (en) 1996-12-30
CZ376397A3 (cs) 1998-06-17
EP0871656B1 (fr) 2002-09-25
UA46776C2 (uk) 2002-06-17
NO975710D0 (no) 1997-12-05
NO975711D0 (no) 1997-12-05
KR19990022583A (ko) 1999-03-25
JPH11504653A (ja) 1999-04-27
ZA964710B (en) 1997-12-08
PL185763B1 (pl) 2003-07-31
TW508357B (en) 2002-11-01
DE69623472D1 (de) 2002-10-10
WO1996040751A1 (fr) 1996-12-19
PT832104E (pt) 2002-12-31
KR100437986B1 (ko) 2004-09-18
TR199701544T1 (xx) 1998-03-21
ATE224910T1 (de) 2002-10-15
CN1182153C (zh) 2004-12-29
NZ310443A (en) 1999-10-28
IL122216A0 (en) 1998-04-05
AU6124296A (en) 1996-12-30
CZ293682B6 (cs) 2004-07-14
CO4700526A1 (es) 1998-12-29
HRP960277A2 (en) 1997-10-31
NO317670B1 (no) 2004-11-29
HUP9801817A2 (hu) 1998-11-30
NO318384B1 (no) 2005-03-14
CN1187199A (zh) 1998-07-08
KR19990022582A (ko) 1999-03-25
SK165397A3 (en) 1998-10-07
HU228071B1 (hu) 2012-09-28
US5831002A (en) 1998-11-03
TR199701545T1 (xx) 1998-04-21
PT871656E (pt) 2002-12-31
NO975711L (no) 1998-01-30
PL185762B1 (pl) 2003-07-31
AU725164B2 (en) 2000-10-05
PL323726A1 (en) 1998-04-14
IL122216A (en) 2002-02-10
HRP960257A2 (en) 1998-02-28
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
ES2188759T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
SK282466B6 (sk) Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie
AU679479B2 (en) Dolostatin analog
US7662786B2 (en) Dolastatin 15 derivatives
IL166853A (en) Antineoplastic peptides, their preparation and various uses thereof
SK282467B6 (sk) Peptidy, farmaceutický prostriedok s ich obsahom a ich použitie
AU775090B2 (en) Antineoplastic peptides

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG, WIESBADEN, DE

Free format text: FORMER OWNER: ABBOTT GMBH & CO. KG, WIESBADEN, DE

Effective date: 20141020

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150603